Q-omics provides the consensus-scored DPH7 profile across patient tissues and cancer cell-line models. DPH7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DPH7 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, DPH7 RNA expression shows 20,014 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where DPH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPH7 survival associations across molecular data types. DPH7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPH7 RNA expression–survival associations across cancer types. High DPH7 expression shows unfavorable associations in KIRC, ACC, COAD, LIHC and KICH, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DPH7 RNA expression.
This table summarizes DPH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DPH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPH7 shows higher tumor expression in COAD, LIHC, HNSC, READ, STAD and BLCA. The COAD box plot shows higher DPH7 RNA expression in tumor versus normal tissue (log2 FC = +1.347, t-test p < 0.001).
This table shows molecular features associated with DPH7 in patient tissues and cancer cell lines. In patient samples, DPH7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
